title: A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients.
abstract: BACKGROUND
  To evaluate the efficacy and safety of treatments for advanced non-small-cell lung cancer in elderly patients aged 75 years or older, we conducted a phase II study of cisplatin and docetaxel administered in three consecutive weekly infusions.
  
  
  METHODS
  The eligibility criteria for the study included the presence of chemotherapy-naive advanced non-small-cell lung cancer, age > or =75 years, Eastern Cooperative Oncology Group performance status of 0 or 1, a measurable lesion, adequate organ functions and signed informed consent. The chemotherapy regimen consisted of cisplatin (25 mg/m(2)) and docetaxel (20 mg/m(2)) on days 1, 8 and 15 every 4 weeks.
  
  
  RESULTS
  Between February 2000 and March 2002, 34 elderly patients with non-small-cell lung cancer were enrolled in the study and 33 patients were treated. Two complete responses and 15 partial responses were obtained for an objective response rate of 52% in 33 treated patients. The median survival period was 15.8 months, and the 1-year survival rate was 64%. Toxicities were mild with no grade 4 toxicities. Only grade 3 leukopenia (6%), neutropenia (12%), anemia (3%), hyponatremia (3%) and nausea/vomiting (3%) were observed.
  
  
  CONCLUSIONS
  Cisplatin and docetaxel administered in three consecutive weekly infusions was safe and effective for the treatment of elderly patients with chemotherapy-naive non-small-cell lung cancer.
authors.affiliation: Department of Internal Medicine, National Cancer Center Hospital, Tokyo, Japan. yohe@ncc.go.jp
authors.forename: Y
authors.initials: Y
authors.lastname: Ohe
authors.forename: S
authors.initials: S
authors.lastname: Niho
authors.forename: R
authors.initials: R
authors.lastname: Kakinuma
authors.forename: K
authors.initials: K
authors.lastname: Kubota
authors.forename: H
authors.initials: H
authors.lastname: Ohmatsu
authors.forename: K
authors.initials: K
authors.lastname: Goto
authors.forename: H
authors.initials: H
authors.lastname: Nokihara
authors.forename: H
authors.initials: H
authors.lastname: Kunitoh
authors.forename: N
authors.initials: N
authors.lastname: Saijo
authors.forename: H
authors.initials: H
authors.lastname: Aono
authors.forename: K
authors.initials: K
authors.lastname: Watanabe
authors.forename: M
authors.initials: M
authors.lastname: Tango
authors.forename: A
authors.initials: A
authors.lastname: Yokoyama
authors.forename: Y
authors.initials: Y
authors.lastname: Nishiwaki
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D000077143:Docetaxel; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D012449:Safety; D016019:Survival Analysis; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin